1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
This listing may be outdated. Verify details at the official source before applying.
Find similar grantsARPA-H Evidence-Based Validation & Innovation for Rapid Therapeutics in Behavioral Health (EVIDENT) Initiative is sponsored by Advanced Research Projects Agency for Health (ARPA-H). This initiative focuses on multimodal, longitudinal data collected in registered clinical trials testing rapid-acting interventions for behavioral health, including neuroplastogens (psychedelics), neuromodulation, and digital therapeutics.
Get a weekly digest of new grants like this
A free weekly digest of new foundation and federal funding opportunities as they're added to Granted. Unsubscribe anytime.
Or search similar grants →According to the current listing, eligibility includes: Research organizations, particularly those in states with existing or developing psychedelic research legislation, are encouraged to engage with their state health agencies for partnership opportunities. Confirm the full requirements in the official notice before applying.
The current listing shows up to $139.4 million total, with at least $50 million for state matching funds. Verify award ceilings, matching requirements, and allowable costs in the official notice.
ARPA-H Evidence-Based Validation & Innovation for Rapid Therapeutics in Behavioral Health (EVIDENT) Initiative is funded by Advanced Research Projects Agency for Health (ARPA-H). Verify program details on the funder's official page before applying.
Start from the official opportunity page linked in this listing — it carries the sponsor's submission instructions.
The Emerging Health Innovators solicitation drops on SAM.gov by the end of September 2026 with 16 named topic areas, an eight-year terminal-degree ceiling, and an eligibility screen that bars national labs, FFRDCs, UARCs, and anyone who has ever led an ARPA prime award. Proposers' Day is October 13. Here is how to read the design.
Read articleARPA-H's 2026 SBIR/STTR BAA opens seven transformative health topics with $600K Phase I and $3.5M Phase II contracts — non-dilutive, milestone-driven money. The July 10 Solution Summary gate decides who ever gets to pitch. Here's how the ARPA-H model differs from NIH and how small health-tech firms actually get through the funnel.
Read articleARPA-H's FY2026 SBIR/STTR solicitation closes its Solution Summary stage July 10, with seven named topics spanning women's health, autoimmune diagnostics, toxin removal, and neurosurgical robotics. Awards run up to $600K for Phase I and $3.5M for Phase II — but they are contracts, not grants, and the four-to-six-page summary is the gate that filters out most applicants. Here is how ARPA-H's model actually works and how to win the first stage.
Read article